News

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
EconoTimes1h
Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
The Hill4d
What’s the difference between Ozempic, Wegovy, other weight loss drugs?
Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...
NBC Connecticut4d
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. Get top ...
Hindustan Times3d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Zepbound, the American firm’s weight-loss jab, was approved in its home country in November 2023, more than two years after Wegovy, made by Novo Nordisk, a Danish rival. Yet in 2024 Zepbound ...